Compare MRBK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | RNA |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.5M | 222.5M |
| IPO Year | 2018 | 2025 |
| Metric | MRBK | RNA |
|---|---|---|
| Price | $20.17 | $12.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $20.75 | ★ $69.26 |
| AVG Volume (30 Days) | 149.5K | ★ 229.2K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 30.34 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $6,316,000.00 | N/A |
| Revenue This Year | $25.40 | $88.12 |
| Revenue Next Year | $8.15 | $18.11 |
| P/E Ratio | $121.35 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $13.81 | $11.40 |
| 52 Week High | $21.59 | $73.06 |
| Indicator | MRBK | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 40.63 |
| Support Level | $18.42 | $11.95 |
| Resistance Level | $20.72 | $14.05 |
| Average True Range (ATR) | 0.65 | 0.52 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 68.46 | 14.17 |
Meridian Corp is a bank holding company based in the United States. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal and business lending and deposit services. It operates in three reportable segments, including Bank, Wealth, and Mortgage. Meridian generates maximum revenue from the Bank segment, which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans. Geographically, it operates in Pennsylvania, New Jersey, and Delaware, as well as in the Central Maryland market and southwest Florida, U.S.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.